Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EpiVacCorona Phase 3 for COVID-19 Prevention
NCT04780035Phase 3Completed
- Start
- Nov 2020
- Primary completion
- Aug 2021
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of EpiVacCorona in coronavirus disease 2019 (COVID-19). Started Nov 2020; status: completed.
02
Drugs
EpiVacCorona
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04780035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04780035.